Xi'an, China

Xin Wang

This inventor holds 2 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Huawei Cloud Computing Technologies Co., Ltd., The First Affiliated Hospital of Xi'an Jiao Tong University, Xidian University. Active years: 2023-2026.

USPTO Granted Patents = 2 

% Patents Active = 50.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xin Wang

Introduction

Xin Wang is a notable inventor based in Xi'an, China. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of infections. His work exemplifies the intersection of innovation and healthcare.

Latest Patents

Xin Wang holds a patent for the use of Belinostat or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating infections. This patent discloses the use of Belinostat in developing effective treatments, along with related methods and compositions. His innovative approach has the potential to impact the pharmaceutical industry positively.

Career Highlights

Throughout his career, Xin Wang has worked with prominent organizations, including Huawei Cloud Computing Technologies Co., Ltd. and The First Affiliated Hospital of Xi'an Jiao Tong University. His experience in these institutions has allowed him to develop and refine his innovative ideas.

Collaborations

Xin Wang has collaborated with several professionals in his field, including Bing Liu and Denghui Liu. These partnerships have contributed to his research and development efforts, enhancing the quality and impact of his work.

Conclusion

Xin Wang's contributions to the field of pharmaceuticals through his innovative patent and career highlights demonstrate his commitment to advancing healthcare solutions. His work continues to inspire future innovations in the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…